Hacking and art mixed on Friday in a freshly launched dating Web site that lets visitors seek mates by sifting through profile pictures mined from Facebook.
Lovely-faces.com boasted Facebook pictures of about 250,000 people searchable in categories that included nationality, gender, funny, smug and “climber.”
The creators of the online “dating agency” were identified at the Web site as artists Paolo Cirio and Alessandro Ludovic.
“Our mission was to give all these virtual identities a new shared place to expose themselves freely, breaking Facebook’s constraints and boring social rules,” the Web site authors said in an online statement datelined in Berlin.
The artists explained that a million “stolen” Facebook profile pictures were analyzed using facial recognition software that filtered images by expressions.
“Immersing ourselves in the resulting database was a hallucinatory experience as we dove into hundreds of thousands of profile pictures and found ourselves in toxicated by the endless smiles, gazes and often leering expressions,” the artists said.
“So we established a new Web site (lovely-faces.com) giving them justice and granting them the possibility of soon being face to face with anybody who is attracted by their facial expression and related data,” they said.
Facebook frowned on lovely-faces, saying that “scraping” or mining information violates the terms of service at the world’s leading online social network. Facebook was investigating and vowed to take “appropriate” action.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very